Biotechnological innovations in the pharmaceutical industry in Poland 2009: Development forecasts for biotechnology sector for 2009-2011

• Publication date: August 2009

Report Description: Biotechnological innovations in the pharmaceutical industry in Poland 2009 provides a comprehensive overview of the biotechnology market in Poland. Covering major industry trends and events, it touches on both domestic and international occurrences that have significance to the Polish market. The report also investigates the size of the market and the most important innovations relevant to the pharmaceutical sect...

Report Description:

Biotechnological innovations in the pharmaceutical industry in Poland 2009 provides a comprehensive overview of the biotechnology market in Poland. Covering major industry trends and events, it touches on both domestic and international occurrences that have significance to the Polish market. The report also investigates the size of the market and the most important innovations relevant to the pharmaceutical sector in recent years. From an operational point of view, the report profiles the major players active on the Polish market, as well as the legislative setting they face. A directory of the approximately 20 biopharmaceutical companies and developmental forecasts up to 2011 is included.

If you are looking for:

- the value of biotechnology market Polish pharmaceutical industry.
- details on Polish biotech firms investing in development of domestic and international market .
- data on niche biotech market segments in Poland .
- key players on the market profiles.
- undergoing investments in Poland.
- legislation briefing regarding biotechnology market in Poland.
… this is a report for you!

Biotechnology Industry in Poland

Table of content

Report methodology 7

Executive summary 11

Overview of the Polish market of pharmaceutical biotechnology 15

Key events and trends in the biotechnology sector
in Poland 15
Key trends and events in 2007-2009 15
Events and trends anticipated for 2009-2011 17
Key characteristics of the Polish market of biotechnology in pharmaceutics 17
Value of the Polish market of pharmaceutical biotechnology 2003-2011 19

Biotech firms in Poland 21

Foreign investment on the Polish pharmaceutical biotechnology market 22
Number and classification of Polish biotech firms 23
Overview of the largest biotech firms on the Polish pharmaceutical market 23
Biotech companies connected with the pharmaceutical industry 33

Selected biotechnological innovations of the Polish pharmaceutical industry 35

Stem cell therapy: Celther 36
siRNA-based innovative biotech drug:Celon Pharna 37
Modified monoclonal antibody therapy: Mabion 39
Tissue engineering and regenerative medicine:
Euroimplant 41
Biotech innovations leading to the development of
new pharmaceutical substances 47
Advanced molecular diagnostics for clinical trials: Read-Gene 47
New technologies for the development of biotech drugs: BioCentrum 49
Innovative screening and comparative research to find bioactive compounds: Proteon Pharmaceuticals 51
BioIT as support for the development of innovative drugs: Selvita 51

Factors material to the development of biotechnology in Poland 53

Human resources 53
Opinions about biotechnology in medicine 56
Legislative environment 58
Key regulations 58
Act on genetically modified organisms 59
Patent law 61
Legislative support for innovation 62
Quality standards in the Polish biotech sector 62
Innovative vaccines against skin and kidney cancer: Biocontract 43
Innovative platform for the development of biotech drugs: Adamed 44
Innovation at the point of contact between science and industry: Biotechnology and Antibiotics Institute 46
Biotechnological innovations in the pharmaceutical industry in Poland 2009
Initiatives supporting the development of innovation and technology transfer 63
Science & technology and industrial parks 63
General overview 63
Current tenants from biotechnology in pharmaceutics and related fields in selected technology parks in Poland 64
Clusters 71
EU funding for the development of biotechnology innovations 73
Access to higher risk capital 77

List of graphs 79

List of tables 81

About the Author 83

Contact the Author 84